Qian Du
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Qian Du has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Dan Deng
Department of Dermatology, Shanghai Children’s Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China
1 shared publication Donglin Zhang
BGI Cell, Shenzhen, Guangdong, China
1 shared publicationFeiyun Chen
Clin Lab, BGI Genomics, Shanghai, China
1 shared publicationFengping Xu
BGI Cell, Shenzhen, Guangdong, China
1 shared publicationHua Wan
BGI Cell, Shenzhen, Guangdong, China
1 shared publication- Jiale Han
Stomatology Hospital Affiliated to Tongji University, Tongji University, Shanghai, China
1 shared publication
Latest Publications
- Open Access
Single-cell RNA sequencing profiles age-related transcriptional landscapes in human hair follicle cells
- Open Access
- 1 January 2025
- Published by Wiley in Journal of Diabetes Research
- Vol. 2025 (1) , 4656485
Revealing the Mechanisms of Shikonin Against Diabetic Wounds: A Combined Network Pharmacology and In Vitro Investigation
Background: Shikonin (SHK) possesses extensive pharmacological effects including antimicrobial and anti‐inflammatory properties for diabetic wound (DW), while its molecular mechanism remains to be clarified. In this study, we investigated the potential mechanisms of SHK in treating DW by combining network pharmacology and in vitro experiments. Methods: We obtained potential targets for SHK and DW from the publicly available database. Based on the interaction network and conducting GO and KEGG pathway enrichment analysis, we constructed a target pathway network to explore the relationship between SHK and DW. To validate the mechanism of SHK, we established an in vitro experimental model. Results: Sixty intersecting targets between SHK and DW were obtained, and the top 10 targets of the protein–protein interaction (PPI) network included AKT1, SRC, EGFR, CASP3, MMP9, PPARG, ESR1, ANXA5, MMP2, and JAK2. Based on target–pathway networks, the PI3K‐AKT signaling pathway was found to be a signaling pathway with low p value in enrichment analysis. In vitro experiments revealed that SHK significantly promoted angiogenesis. Meanwhile, SHK could inhibit the high glucose‐induced human umbilical vein endothelial cell dysfunction through regulating the PI3K‐AKT pathway. Conclusion: This study initially revealed the molecular mechanism of SHK in DW by multitarget and multipathway. The PI3K–AKT signaling pathway, MAPK signaling pathway, and AGE‐RAGE signaling pathways may be the main pathways of SHK in treating DW.
- 1 January 2025
- Published by Wiley in Journal of Diabetes Research
- Vol. 2025 (1) , 4656485
Open AccessRevealing the Mechanisms of Shikonin Against Diabetic Wounds: A Combined Network Pharmacology and In Vitro Investigation
Background: Shikonin (SHK) possesses extensive pharmacological effects including antimicrobial and anti‐inflammatory properties for diabetic wound (DW), while its molecular mechanism remains to be clarified. In this study, we investigated the potential mechanisms of SHK in treating DW by combining network pharmacology and in vitro experiments. Methods: We obtained potential targets for SHK and DW from the publicly available database. Based on the interaction network and conducting GO and KEGG pathway enrichment analysis, we constructed a target pathway network to explore the relationship between SHK and DW. To validate the mechanism of SHK, we established an in vitro experimental model. Results: Sixty intersecting targets between SHK and DW were obtained, and the top 10 targets of the protein–protein interaction (PPI) network included AKT1, SRC, EGFR, CASP3, MMP9, PPARG, ESR1, ANXA5, MMP2, and JAK2. Based on target–pathway networks, the PI3K‐AKT signaling pathway was found to be a signaling pathway with low p value in enrichment analysis. In vitro experiments revealed that SHK significantly promoted angiogenesis. Meanwhile, SHK could inhibit the high glucose‐induced human umbilical vein endothelial cell dysfunction through regulating the PI3K‐AKT pathway. Conclusion: This study initially revealed the molecular mechanism of SHK in DW by multitarget and multipathway. The PI3K–AKT signaling pathway, MAPK signaling pathway, and AGE‐RAGE signaling pathways may be the main pathways of SHK in treating DW.
- 15 March 2023
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 64 (2) , 297-299
Porokeratotic lichen planus of the lower extremities
- 15 March 2023
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 64 (2) , 297-299
Porokeratotic lichen planus of the lower extremities
- 17 January 2022
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 36 (6) , E441-E443
Crisaborole: an emerging therapy for prurigo pigmentosa
- 17 January 2022
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 36 (6) , E441-E443
Crisaborole: an emerging therapy for prurigo pigmentosa